Comparison of rituximab induction and maintenance regimens in anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: PK/PD modelling of ANCA and gammaglobulin levels in real-world patients
Abstract
BACKGROUND: We aimed to provide pharmacokinetic-pharmacodynamic (PK/PD) rationale for selecting the optimal induction and maintenance dosing regimens in ANCA-associated vasculitis (AAV) using a population modelling approach based on PK, ANCA, and gammaglobulins data from a real-world cohort. METHODS: weekly for 4 weeks and 1000 mg on day 0 and 14) and maintenance regimens (500 mg every 6 months [Q6M], 500 mg Q6M starting at month 4, 1000 mg Q4M, 500 mg Q4M) were performed in 1000 virtual patients. Dosing regimens were compared using a clinical utility score that equally weighted the percentage of patients in serological remission and at risk of hypogammaglobulinaemia (<6 g/L). FINDINGS: The PK/PD model satisfactorily described the relationship between rituximab, gammaglobulins and ANCA concentrations over time. Both induction regimens resulted in a similar number of patients achieving serological remission and hypogammaglobulinaemia at 6 months. In the maintenance phase, increasing the dose (to 1000 mg) or the frequency of administration (Q4M versus Q6M) was associated with a higher number of patients with serological remission at month 24, but also with a higher risk of hypogammaglobulinaemia. In the maintenance phase, 500 mg Q6M (start at month 4 or 6), had a significantly higher utility score than 1000 mg Q4M. INTERPRETATION: This PK/PD study can inform clinical decisions regarding the choice between different rituximab induction and maintenance regimens in patients with AAV in daily practice. FUNDING: This study received no funding.
Related
- Real-world comparison of treatments with antibodies targeting the CGRP pathway or botulinum toxin type A for resistant migraine
- A Comparison of Neutrophil Secretion of Cytokines and NET Formation in Response to Lipopolysaccharide and Group B Streptococcus (GBS) in Mice and Rats in vitro
- Development and application of KASP markers for cytoplasmic male sterility genes in polima CMS and ogura CMS systems in rapeseed (Brassica napus L.)
- Protocol for monitoring cytoplasmic Ca2+ dynamics using Fura Red-AM on a Zeiss Axio Observer microscope
- PKA-regulated carbohydrate production protects cells by altering cytoplasmic biophysical properties
BibTeX
@article{pasquiers2026comparison,
title = {{Comparison of rituximab induction and maintenance regimens in anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: PK/PD modelling of ANCA and gammaglobulin levels in real-world patients}},
author = {Blaise Pasquiers and Benoit Blanchet and Xavier Puéchal and Xavier Declèves and Pascal Cohen and Claire Goulvestre and Marion Casadevall and Inès Benhabiles and Michel Vidal and David Ternant and Benjamin Terrier and Alicja Puszkiel},
journal = {EBioMedicine},
year = {2026},
month = nov,
doi = {10.1016/j.ebiom.2025.105989},
url = {https://hal.science/hal-05864961v1},
note = {CC BY},
}
RIS
TY - JOUR
TI - Comparison of rituximab induction and maintenance regimens in anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: PK/PD modelling of ANCA and gammaglobulin levels in real-world patients
AU - Blaise Pasquiers
AU - Benoit Blanchet
AU - Xavier Puéchal
AU - Xavier Declèves
AU - Pascal Cohen
AU - Claire Goulvestre
AU - Marion Casadevall
AU - Inès Benhabiles
AU - Michel Vidal
AU - David Ternant
AU - Benjamin Terrier
AU - Alicja Puszkiel
PY - 2026
DA - 2026/11/15
JO - EBioMedicine
DO - 10.1016/j.ebiom.2025.105989
UR - https://hal.science/hal-05864961v1
AB - BACKGROUND: We aimed to provide pharmacokinetic-pharmacodynamic (PK/PD) rationale for selecting the optimal induction and maintenance dosing regimens in ANCA-associated vasculitis (AAV) using a population modelling approach based on PK, ANCA, and gammaglobulins data from a real-world cohort. METHODS: weekly for 4 weeks and 1000 mg on day 0 and 14) and maintenance regimens (500 mg every 6 months [Q6M], 500 mg Q6M starting at month 4, 1000 mg Q4M, 500 mg Q4M) were performed in 1000 virtual patients. Dosing regimens were compared using a clinical utility score that equally weighted the percentage of patients in serological remission and at risk of hypogammaglobulinaemia (<6 g/L). FINDINGS: The PK/PD model satisfactorily described the relationship between rituximab, gammaglobulins and ANCA concentrations over time. Both induction regimens resulted in a similar number of patients achieving serological remission and hypogammaglobulinaemia at 6 months. In the maintenance phase, increasing the dose (to 1000 mg) or the frequency of administration (Q4M versus Q6M) was associated with a higher number of patients with serological remission at month 24, but also with a higher risk of hypogammaglobulinaemia. In the maintenance phase, 500 mg Q6M (start at month 4 or 6), had a significantly higher utility score than 1000 mg Q4M. INTERPRETATION: This PK/PD study can inform clinical decisions regarding the choice between different rituximab induction and maintenance regimens in patients with AAV in daily practice. FUNDING: This study received no funding.
SN - 2352-3964
ER -